There are currently 2337 ongoing clinical trials involving Lymphoma
Of the 2337 trials,856 trials are in Phase II
Furthermore, 1224 trials are in Phase I
The global pharmaceutical industry is steadily developing new drugs for Lymphoma, an Oncology condition. The largest number of ongoing clinical trials for Lymphoma is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Lymphoma-related drug trials.
National Cancer Institute US: The leading ongoing Lymphoma related clinical trial sponsor
National Cancer Institute US is the top sponsor for Lymphoma-related ongoing clinical trials.
University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, City of Hope, Dana-Farber Cancer Institute Inc, and F. Hoffmann-La Roche Ltd are among other notable clinical trial sponsors involved in Lymphoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Lymphoma
Pembrolizumab (Keytruda), Lenalidomide (Revlimid), and Nivolumab (Opdivo, Opdyta) are among the key marketed drugs involving Lymphoma.
Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent. It functions via Programmed Cell Death Protein 1 Antagonist mechanism of action. Keytruda is formulated as a lyophilized powder for solution, solution concentrate for intravenous route of administration. Keytruda is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation is positive, a BRAF inhibitor. Keytruda as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Pembrolizumab was first approved in 2014 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Merck Sharp & Dohme Corp.
Lenalidomide (Revlimid) is a thalidomide analogue and an immunomodulatory imide drug (IMiD). It functions via the Protein cereblon (CRBN) Activator mechanism of action. It is formulated as hard gelatin capsules for the oral route of administration. Revlimid in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM), as maintenance therapy in patients with multiple myeloma following autologous hematopoietic stem cell transplantation (auto-HSCT). Lenalidomide was first approved in 2005 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Celgene Corp.
United States of America
China
United States of America
United States of America
United States of America
United States of America
United States of America
United Kingdom
Switzerland
France
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer